Clinical and pharmacological group: & nbsp

Means that affect the metabolism of the prostate gland, and correctors urodynamics

Included in the formulation
  • Sonirid Duo
    capsulespills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • АТХ:

    G.04.C.A.02   Tamsulosin

    G.04.C.B.01   Finasteride

    Pharmacodynamics:

    Complex preparation.

    Tamsulosin

    Selectively blocks postsynaptic α1A-adrenoreceptors located on the neck of the bladder and smooth muscle cells of the prostate gland, as well as in the prostatic urethra.

    It improves the outflow of urine, reduces irritation and eliminates the manifestations of obstruction of the urinary tract due to benign prostatic hyperplasia.

    Finasteride

    Inhibits the intracellular enzyme 5-α-reductase II type, which converts testosterone androgen 5-α-dihydrotestosterone, which stimulates the growth of the prostate. As a result, the development of prostatic hypertrophy ceases.

    Pharmacokinetics:

    Tamsulosin

    After oral administration, it is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 4-5 hours. The connection with plasma proteins is up to 99%.

    Therapeutic effect develops 2 weeks after the beginning of the admission. Metabolism in the liver to metabolites that retain pharmacological activity.

    The half-life is 9-13 hours.Elimination of the kidneys in the form of metabolites, about 9% unchanged.

    Finasteride

    After oral administration, an empty stomach is absorbed up to 80% in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 2 hours. The connection with plasma proteins is 90%.

    Penetrates through the blood-brain barrier. Metabolism in the liver.

    The half-life is 6 hours. Elimination with feces.

    Indications:

    It is used to treat benign prostatic hyperplasia.

    XIV.N40-N51.N40   Hyperplasia of the prostate

    Contraindications:

    Age to 18 years, hepatic and renal failure, pregnancy and lactation, individual intolerance.

    Carefully:

    Risk of development of obstructive uropathy, planning of operative treatment of cataract.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Not applicable. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, 1 capsule of tamsulosin (400 mcg) and 1 tablet of finasteride (5 mg) once a day.

    The highest daily dose: 1 capsule of tamsulosin (400 mcg) and 1 tablet of finasteride (5 mg).

    The highest single dose: 1 capsule of tamsulosin (400 mcg) and 1 tablet of finasteride (5 mg).

    Side effects:

    Tamsulosin

    Central and peripheral nervous system: asthenia, headache, dizziness, syncope, sleep disorders.

    The cardiovascular system: orthostatic hypotension, tachycardia, cardialgia.

    Digestive system: nausea, vomiting, diarrhea, or constipation.

    Musculoskeletal system: backache.

    Sense organs: rhinitis, visual impairment.

    Dermatological reactions: a rash.

    Reproductive system: priapism, violation of libido, retrograde ejaculation.

    Allergic reactions.

    Finasteride

    Digestive system: gastralgia.

    Sense organs: clouding of the lens.

    Reproductive system: erectile dysfunction, decreased libido, pain in the testicles.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Cimetidine increases the concentration of tamsulosin in the blood plasma.

    Furosemide lowers the concentration of tamsulosin in the blood plasma.

    Warfarin and diclofenac increase the rate of excretion of tamsulosin.

    When used simultaneously with other α1-adrenoceptor increases the risk of developing arterial hypotension.

    Special instructions:

    During the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up